Purchase Order 75D30126P20965
Award Date 4/10/26
Potential Completion Date 4/15/26
Potential Value $2.8K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Atlanta, GA 30329, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response to Emergent Biodefense Operations Lansing LLC, a for-profit manufacturer of medical countermeasures. The $1,174,464,339.10 firm fixed-price contract is for the production of BioThrax, the only FDA-licensed vaccine for the prevention of anthrax disease, which is a critical component of the U.S. government's strategic national stockpile. The...
- The U.S. Department of the Army Acquisition Support Center Joint PEO Chemical and Biological Defense awarded Emergent Biodefense Operations Lansing LLC a $66.9 million firm fixed-price delivery order on January 4, 2026, for the procurement of BioThrax (Anthrax Vaccine Absorbed). The contract, which carries no set-aside designation, is scheduled for completion by September 30, 2029, with manufacturing and delivery operations based in Lansing, Michigan. This delivery order is issued under an...
- <p>This is a contract awarded by the Department of Health and Human Services (HHS) Centers for Disease Control and Prevention (CDC) to Emergent Biodefense Operations Lansing LLC, also known as Emergent Biodefense, for the maintenance of a smallpox license. The contract is a delivery order with a firm fixed price of $38,430,000.00 and a completion date of January 31, 2019. The place of performance is located in Cambridge, Massachusetts. The contract does not have a set-aside designation.</p>
- The U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded Emergent Product Development Gaithersburg Inc. a firm fixed price contract valued at $804.9 million on August 30, 2019, for the manufacture and delivery of ACAM2000, a live vaccinia smallpox vaccine. The contract, which extends through August 29, 2029, supports the federal government's medical countermeasures stockpiling and pandemic preparedness initiatives. Work will be...
- The Defense Logistics Agency (DLA) awarded a $1,097.44 delivery order to AmerisourceBergen Drug Corp for the supply of Trumenba 120 mcg/0.5 ml vaccine in 0.5 ml units. The contract was competitively awarded without set-aside provisions and carries a firm fixed price. The award was executed on June 2, 2025, with an ultimate completion date of June 3, 2025, and performance will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a $2,125.04 delivery order to AmerisourceBergen Drug Corp for Trumenba 120 MCG/0.5 ML vaccine on September 19, 2025, with an ultimate completion date of September 22, 2025. This competitively awarded, firm fixed-price contract is classified as a delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The U.S. Defense Department's Medical Supply Chain awarded AmerisourceBergen Drug Corp a $1,495.76 firm fixed-price delivery order for Engerix-B 10 microgram vaccine (10-count) on July 14, 2025, with an ultimate completion date of July 15, 2025. This competitively awarded, non-set-aside contract was issued under the company's existing Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) Troop Support Medical, designated as SPE2DX. The place of performance is...
- This is a $43,794,113.43 cost-plus-fixed-fee definitive contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response to Emergent Product Development Gaithersburg Inc., a for-profit manufacturer, for the advanced development of NuThrax (Anthrax Vaccine Absorbed with CPG 7909) or AV7909. The contract has an ultimate completion date of July 31, 2019 and was awarded on March 23, 2015. There is no set-aside designation for this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of ENGERIX-B 20 MCG/ML vaccine at a ceiling value of $1,435.25. This is a firm fixed price delivery order with no set-aside designation, reflecting competitive procurement practices. The work is performed at AmerisourceBergen's Conshohocken, Pennsylvania location, with an ultimate completion date of September 11, 2025. This delivery order is executed under...
- The Defense Logistics Agency awarded a delivery order valued at $23,145.08 to AmerisourceBergen Drug Corp for ENGERIX-B 20 MCG/ML vaccine on September 9, 2025, with completion scheduled for September 10, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical...